1. NMDAR NR1 anti NMDAR encephalitis
2. amphiphysin-- stiff person syndrome, encephalomyelitis,limbic encephalomyelitis, sensorimotor neuropathy
3. ARHGAP 25, GRAF -- subacute inflammatory cerebellar ataxia
4. CASPR2 (contactin associated protein 2)- Morvan syndrome, neuromyotonia, limbic encephalitis
5. MOG -- ADEM, MS, CIS, NMO-SD
6. GAD 65-- stiff person syndrome, cerebellar syndrome, limbic encephalitis, epilepsy
7. Ma2-- brainstem encephalitis, limbic encephalitis, cerebellar syndrome, polyneuropathy
8. Yo- brainstem encephalitis, cerebellar syndrome
9. Ma1 - brainstem encephalitis, limbic encephalitis, cerebellar syndrome, polyneuropathy
German study published in Ann Neurol July 23 show equal prevalence of these antibodies in healthy and diseased individuals. Titers and Ig class distribution also were similar for above antigens.
NMDAR were found in 10-20 percent of normal individuals, and are higher among those who suffered influenza.
Weinshenker-- Validity depends on pretest probability that patients have the illness.
2. amphiphysin-- stiff person syndrome, encephalomyelitis,limbic encephalomyelitis, sensorimotor neuropathy
3. ARHGAP 25, GRAF -- subacute inflammatory cerebellar ataxia
4. CASPR2 (contactin associated protein 2)- Morvan syndrome, neuromyotonia, limbic encephalitis
5. MOG -- ADEM, MS, CIS, NMO-SD
6. GAD 65-- stiff person syndrome, cerebellar syndrome, limbic encephalitis, epilepsy
7. Ma2-- brainstem encephalitis, limbic encephalitis, cerebellar syndrome, polyneuropathy
8. Yo- brainstem encephalitis, cerebellar syndrome
9. Ma1 - brainstem encephalitis, limbic encephalitis, cerebellar syndrome, polyneuropathy
German study published in Ann Neurol July 23 show equal prevalence of these antibodies in healthy and diseased individuals. Titers and Ig class distribution also were similar for above antigens.
NMDAR were found in 10-20 percent of normal individuals, and are higher among those who suffered influenza.
Weinshenker-- Validity depends on pretest probability that patients have the illness.
No comments:
Post a Comment